KROS

UNKNOWN

Keros Therapeutics, Inc.

CIK: 0001664710

Sell (70% confidence)

Last activity: 3 weeks ago

Financial Metrics

As of Dec 31, 2025 (10-K)

Revenue $243.86M

Insider	Buys	Sells	Net Value	Holdings
Seehra Jasbir CHIEF EXECUTIVE OFFICER	0	1	-$113K	385,708 shares $6.24M
Cho Esther SVP, General Counsel	0	1	-$78K	39,755 shares $650K
Regnante Keith CHIEF FINANCIAL OFFICER	0	1	-$77K	39,261 shares $642K
Lerner Lorena Raquel Chief Science Officer	0	1	-$63K	31,127 shares $509K
BIENAIME JEAN JACQUES OTHER	1	0	$22K	7,450 shares $84K

BUY BIENAIME JEAN JACQUES (OTHER)

2,000 shares @ $11.21

$22K

Mar 9, 2026

Conviction: | View SEC Filing →

SELL Seehra Jasbir (CHIEF EXECUTIVE OFFICER)

7,015 shares @ $16.17

$113K

Feb 19, 2026

Conviction: | View SEC Filing →

SELL Cho Esther (SVP, General Counsel)

4,745 shares @ $16.35

$78K

Feb 18, 2026

Conviction: | View SEC Filing →

SELL Regnante Keith (CHIEF FINANCIAL OFFICER)

4,739 shares @ $16.35

$77K

Feb 18, 2026

Conviction: | View SEC Filing →

SELL Lerner Lorena Raquel (Chief Science Officer)

3,873 shares @ $16.35

$63K

Feb 18, 2026

Conviction: | View SEC Filing →

• This is AI-generated analysis for educational purposes only, not financial advice.

• Insider trading data is derived from SEC Form 4 filings and may contain errors.

• Always conduct your own research and consult qualified financial advisors before making investment decisions.